Business Wire

NV-GSMA

7.1.2020 18:02:07 CET | Business Wire | Press release

Share
GSMA Intelligence: US and European Consumers Cautious on Move to 5G Devices, China and Korea Set to Lead Early Adoption

The smartphone will remain the dominant consumer device into the new decade, but the arrival of 5G will not guarantee a surge in device upgrades, according to new GSMA Intelligence research. A new report, The Future of Devices , published at the Consumer Electronics Show (CES) 2020 in Las Vegas today, provides a wealth of insight on consumer technology adoption trends over the coming years, including the outlook for smartphones, smart speakers, wearables and other emerging categories.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005796/en/

Based on the results of GSMA Intelligence’s 2019 Consumer Survey, the report found that smartphone ownership among adults in most high- and middle-income countries is at 85-95 per cent. However, only 30-40 per cent of survey respondents in significant markets such as the US, Europe and Australia said the arrival of 5G is likely to result in a smartphone upgrade in the short term. By contrast, markets such as China and South Korea will be early adopters; nearly 50 per cent of Chinese consumers say they will buy a 5G phone as soon as they are available.

“The device ecosystem will be critical in shaping the trajectory of 5G adoption,” said Peter Jarich, Head of GSMA Intelligence. “However, it’s a mistake to believe that consumers in every market will look at 5G upgrades in the same way. Operators and device manufacturers will need to understand consumer demand on a granular level if they hope to make the most of the 5G opportunity.”

5G

Mixed picture for smart home and wearables

Fragmentation and a lack of compatibility between manufacturers hamper the adoption of smart home devices. However, this segment is being boosted by the growing popularity of smart speakers, such as Amazon’s Echo devices, which are increasingly acting as a single control point within the home. Smart speakers were the fastest moving category in the 2019 survey, now owned by 21 per cent of households, up ten percentage points over the previous year. Speakers have become a key battleground in the broader development of AI. Amazon and Google are furthest ahead, but both face the challenge of getting customers to go beyond basic functionality to higher-value tasks such as purchasing goods.

Meanwhile, the adoption rates for fitness trackers and smartwatches also picked up in 2019, and are now owned by 21 per cent and 10 per cent of adults, respectively. Millennials show the most substantial ownership rates of these devices, being more tech-savvy than older generations and also benefitting from an employer or insurance-based subsidies. However, the report notes that connected health devices continue to be sorely underrepresented among older populations. Missing older people is a missed opportunity for tech companies and governments, given that such devices can facilitate remote monitoring for a range of conditions, reducing the volume of in-person consultations and the strain on national healthcare systems.

The 2020 edition of The Future of Devices report is available to accredited members of the press on request. This report is based on GSMA Intelligence’s 2019 Consumer Survey, which surveyed 38,000 respondents across 36 key markets, using a blend of online and face-to-face sampling methodologies.

GSMA Intelligence @ #CES2020

GSMA Intelligence will be hosting a seminar dedicated to IoT at the MGM Grand in Las Vegas during CES. During this session, GSMA Intelligence will feature its latest forecasts and expectations for both consumer and enterprise IoT.

Our senior analysts will be available on-site for one-to-one media interviews during the week. We can provide expert commentary across a range of industry topics and discuss all the key announcements and developments. Please contact us at: media@gsmaintelligence.com

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .

Contact:

For the GSMA: GSMA Press Office Isobel Moseley pressoffice@gsma.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye